News Home > News

July 30, 2010
Conatus Pharmaceuticals Acquires Pfizer’s Idun Subsidiary

January 28, 2010
Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination with Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)

October 5, 2009
Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference

June 24, 2009
Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis

June 11, 2008
Conatus Pharmaceuticals Announces Its Lead Drug Candidate Inhibits Liver Fibrosis In A Key Preclinical Model Of Liver Disease

March 25, 2008
Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., As Chief Medical Officer

December 20, 2007
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis

November 5, 2007
Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease

May 23, 2007
Conatus Pharmaceuticals elects Harold E. Van Wart, Ph.D., to its Board of Directors.

May 9, 2007
Conatus Pharmaceuticals completes second closing of $27.5 million private placement financing.

January 3, 2007
Conatus Pharmaceuticals completes $27.5 million private placement financing.

August 24, 2006
Conatus Pharmaceuticals announces new personnel.

August 24, 2006
Conatus Pharmaceuticals announces new Corporate headquarters.